Guideline for Evaluation and Management of Metformin‑Associated Spotting in Women of Reproductive Age

Immediate Evaluation

Obtain a urine or serum β‑hCG test to exclude pregnancy in any woman of reproductive age presenting with new vaginal bleeding. 1
Perform a transvaginal ultrasound to assess endometrial thickness and to rule out polyps, fibroids, or hyperplasia as structural causes of unscheduled bleeding. 2
Consider an endometrial biopsy when the patient is older than 45 years or has risk factors for endometrial cancer (e.g., prolonged amenorrhea with unopposed estrogen exposure, obesity, anovulation). 2

Metformin can restore menstrual cyclicity in women with anovulatory amenorrhea, improving ovulation rates especially in polycystic ovary syndrome, although it is less effective than combined oral contraceptives for cycle regulation. 3

Reassure that spotting during the first 3–6 months of metformin therapy is common and generally benign; most bleeding irregularities resolve spontaneously. 4
Continue metformin at the current dose when bleeding is limited to light spotting, as breakthrough bleeding typically resolves within 3–6 months. 1
Offer a short course of NSAIDs (e.g., mefenamic acid 500 mg three times daily or celecoxib 200 mg once daily for 5–7 days) as first‑line symptomatic treatment for bothersome spotting. 2
If spotting persists or becomes heavy, add short‑term hormonal therapy (low‑dose combined oral contraceptives or estrogen) for 10–20 days, provided there are no contraindications such as a history of venous thromboembolism, smoking > 35 years, or migraine with aura. 1

Screen for sexually transmitted infections as part of the initial work‑up for irregular bleeding. 4
Review concomitant medications (e.g., anticoagulants, antiepileptic drugs, enzyme‑inducing agents) that may precipitate abnormal bleeding. 2
Verify metformin adherence and timing; inconsistent use can contribute to irregular bleeding patterns. 1

Refer to gynecology if bleeding persists beyond 6 months despite appropriate management. 1
Refer if bleeding is heavy enough to require pad/tampon changes more frequently than hourly or if there are clinical signs of anemia (fatigue, dizziness, pallor). 2
Refer if transvaginal ultrasound shows endometrial thickness > 4 mm in a woman with prolonged amenorrhea or any other suspicious sonographic findings. 2
Refer when the patient requests definitive evaluation or when the clinical picture remains unclear after the initial work‑up. 1

Do not discontinue metformin prematurely when it is indicated for metabolic syndrome or prediabetes; manage bleeding symptomatically instead. 3
Do not overlook pregnancy risk—metformin can restore ovulation unpredictably, so provide contraception counseling if pregnancy is not desired. 3